Clinical Applications of DNA Vaccines: Current Progress
Bernadette Ferraro,Matthew P. Morrow,Natalie A. Hutnick,Thomas H. Shin,Colleen E. Lucke,David B. Weiner +5 more
TLDR
The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas.Abstract:
It was discovered almost 20 years ago that plasmid DNA, when injected into the skin or muscle of mice, could induce immune responses to encoded antigens. Since that time, there has since been much progress in understanding the basic biology behind this deceptively simple vaccine platform and much technological advancement to enhance immune potency. Among these advancements are improved formulations and improved physical methods of delivery, which increase the uptake of vaccine plasmids by cells; optimization of vaccine vectors and encoded antigens; and the development of novel formulations and adjuvants to augment and direct the host immune response. The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas. This review focuses on these advances and discusses both preventive and immunotherapeutic clinical applications.read more
Citations
More filters
Journal ArticleDOI
DNA and mRNA vaccination against allergies.
TL;DR: The subtle priming of T helper 1 immunity induced by this vaccine type closely resembles responses of non‐allergic individuals and—by boosting via natural allergen exposure—could suffice for long‐term protection from type I allergy.
Journal ArticleDOI
Synthetic DNA vaccine strategies against persistent viral infections.
TL;DR: Recent improvements to this synthetic platform are focused on in relation to their application in combating persistent virus infection.
Journal ArticleDOI
Electroporation-enhanced delivery of nucleic acid vaccines.
Kate E. Broderick,Laurent Humeau +1 more
TL;DR: This review seeks to introduce the reader to EP as a technology to enhance the delivery of DNA and RNA vaccines and highlight several published clinical trials using this delivery modality.
Journal ArticleDOI
Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy.
Yuka Igarashi,Tetsuro Sasada +1 more
TL;DR: The current status of cancer immunotherapies, especially cancer vaccines, is summarized, the potential problems and solutions for the next breakthrough in cancer immunotherapy are discussed, and several issues remain to be solved to improve their clinical efficacy.
Journal ArticleDOI
Engineering buffering and hydrolytic or photolabile charge shifting in a polycarboxybetaine ester gene delivery platform.
TL;DR: Key parameters important for the PCB-ester platform are revealed and the significance of charge switching to an effective and nontoxic nonviral gene delivery platform is revealed.
References
More filters
Journal ArticleDOI
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more
TL;DR: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk and offer insight for future research.
Journal ArticleDOI
Heterologous protection against influenza by injection of DNA encoding a viral protein
Jeffrey B. Ulmer,John J. Donnelly,Suezanne E. Parker,Gary Rhodes,Philip L. Felgner,V. J. Dwarki,Stanislaw H. Gromkowski,R. Randall Deck,Corrille M. DeWitt,Arthur Friedman,Linda A. Hawe,Karen R. Leander,Douglas Martinez,Helen C. Perry,John W. Shiver,Donna L. Montgomery,Margaret A. Liu +16 more
TL;DR: To generate a viral antigen for presentation to the immune system without the limitations of direct peptide delivery or viral vectors, plasmid DNA encoding influenza A nucleop protein was injected into the quadriceps of BALB/c mice and resulted in the generation of nucleoprotein-specific CTLs.
Journal ArticleDOI
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Susan Buchbinder,Devan V. Mehrotra,Ann Duerr,Daniel W. Fitzgerald,Robin Mogg,David Li,Peter B. Gilbert,Javier R. Lama,Michael Marmor,Carlos del Rio,M. Juliana McElrath,Danilo R. Casimiro,Keith Gottesdiener,Chodakewitz Jeffrey A,Lawrence Corey,Michael N. Robertson +15 more
TL;DR: This cell-mediated immunity vaccine did not prevent HIV-1 infection or reduce early viral level and Mechanisms for insufficient efficacy of the vaccine and the increased HIV- 1 infection rates in subgroups of vaccine recipients are being explored.
Journal ArticleDOI
Genetic immunization is a simple method for eliciting an immune response.
TL;DR: It is reported that an immune response can be elicited by introducing the gene encoding a protein directly into the skin of mice by using a hand-held form of the biolistic system.
Journal ArticleDOI
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations
Ellen F. Fynan,Robert G. Webster,Deborah H. Fuller,Joel R. Haynes,Joseph C. Santoro,Harriet L. Robinson +5 more
TL;DR: By far the most efficient DNA immunizations were achieved by using a gene gun to deliver DNA-coated gold beads to the epidermis, and 95% protection was achieved by two immunizations with beads loaded with as little as 0.4 micrograms of DNA.